Cryoport, Inc. (CYRX): Revenue
$176.18M
Year ended 2025-12-31
$186.45M
Trailing 12 months to 2026-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $176.18M | +12.4% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $156.77M | -7.1% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $168.66M | n/c | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $237.28M | +6.6% | 2025-03-07, From 2022-01-01 |
| 2021-12-31 | $222.61M | +182.9% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $78.70M | +131.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $33.94M | +72.9% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $19.63M | +64.2% | 2020-03-10, From 2018-01-01 |
| 2017-12-31 | $11.95M | +55.7% | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $7.68M | n/a | 2018-03-08, From 2016-01-01 |
| No annual figure between 2015-03-31 and 2016-12-31. | |||
| 2015-03-31 | $3.94M | +47.9% | 2016-06-28, From 2014-04-01 |
| 2014-03-31 | $2.66M | +141.7% | 2015-05-19, From 2013-04-01 |
| 2013-03-31 | $1.10M | +98.1% | 2014-06-25, From 2012-04-01 |
| 2012-03-31 | $555.6K | +16.9% | 2013-06-25, From 2011-04-01 |
| 2011-03-31 | $475.5K | n/a | 2012-06-27, From 2010-04-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | 2025-12-31 | $176.18M | +12.4% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $175.11M | +216.9% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $172.35M | +627.8% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $182.59M | -20.1% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $184.42M | +404.5% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $185.74M | -28.3% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $189.76M | +45.8% |
| Liquidia Corp (LQDA) | 2025-12-31 | $158.32M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $154.90M | +7.4% |
Compare CYRX, PHAT, SNDX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗